Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.

[1]  J. Rosenstock,et al.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. , 2021, The New England journal of medicine.

[2]  J. Shaw,et al.  The Lancet Commission on diabetes: using data to transform diabetes care and patient lives , 2020, The Lancet.

[3]  J. McMurray,et al.  Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) , 2020, Circulation.

[4]  B. Di Camillo,et al.  Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. , 2020, European journal of preventive cardiology.

[5]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[6]  S. Brunton,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date , 2020, Postgraduate medicine.

[7]  D. Xavier,et al.  Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial , 2020, The Lancet Neurology.

[8]  G. Sesti,et al.  Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. , 2020, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[9]  S. Atkin,et al.  A review on the effects of new anti-diabetic drugs on platelet function. , 2020, Endocrine, metabolic & immune disorders drug targets.

[10]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[11]  E. Standl.  GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis. , 2019, The lancet. Diabetes & endocrinology.

[12]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[13]  W. E. Sanabria,et al.  Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. , 2019, Lancet.

[14]  N. Grassly,et al.  Interventions to improve oral vaccine performance: a systematic review and meta-analysis , 2019, The Lancet. Infectious diseases.

[15]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[16]  Sandeep R. Das,et al.  2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2018, Journal of the American College of Cardiology.

[17]  O. Godefroy,et al.  Systematic Review and Meta-Analysis of Prevalence in Post-Stroke Neurocognitive Disorders in Hospital-Based Studies , 2018, Dementia and Geriatric Cognitive Disorders.

[18]  A. Saremi,et al.  Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. , 2018, The lancet. Diabetes & endocrinology.

[19]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[20]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[21]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[22]  Adrian F Hernandez,et al.  Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. , 2017, The lancet. Diabetes & endocrinology.

[23]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[24]  B. Zinman,et al.  Liraglutide and Renal Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[25]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[26]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[27]  A. Tahrani,et al.  Future glucose-lowering drugs for type 2 diabetes. , 2016, The lancet. Diabetes & endocrinology.

[28]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[29]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[30]  D G Altman,et al.  Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.